Activity inhibition of cytolytic lymphocytes by omeprazole

Scandinavian Journal of Immunology

Volumn 44, Issue 3, 1996, Pages 204-214

  Scaringi, L ^a   Cornacchione, P ^a   Fettucciari, K ^a   Rosati, E ^a   Rossi, R ^a   Marconi, P ^a   Capodicasa, E ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; OMEPRAZOLE; PROSTAGLANDIN; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

EID: 0029772522     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1996.d01-300.x     Document Type: Article

References (59)

1. Maton PN. Drug therapy: omeprazole. N Engl J Med 1991;324:965-75.
2. Larson H, Carlsson E, Junggren U et al. Inhibition of gastric acid secretion by omepruzole in the dog and rat. Gastroenterology 1983;85:900-7.
3. + pump in plasma membranes of hog stomach. J Biol Chem 1976;251:7690-8.
4. +)-ATPase. Nature 1981;290:159-61.
5. Wallmark B, Lindberg P. Mechanism of action of omeprazole. ISI Atlas of Science Pharmacol 1987;1:158-61.
6. +)-ATPase within the parietal cell. Biochem Biophys Acta 1984;778:549-58.
7. +-pumping into intracellular organelles. Ann Rev Physiol 1986;48:403-13.
8. Forgac M. Structure and function of the vascular class of ATP-driven proton pumps. Physiol Rev 1989;69:765-96.
9. 245. Gut 1992;33:617-21.
10. Kaunitz JD, Sachs G. Identification of a vanadate-sensitive potassium-dependent proton pump from rabbit colon. J Biol Chem 1986;261:14005-10.
11. Henkart PA. Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol 1985;3:31-58.
12. Krahenbuhl O, Tschopp J. Perforin-induced pore formation. Immunol Today 1991;12:399-402.
13. Podack ER, Hengartner H, Lichtenheld MG. A central role of perforin in cytolysis? Annu Rev Immunol 1991;9:129-57.
14. Yagita H, Nakat M, Kawasaki A, Shinkai Y, Okumura K. Role of perforin in lymphocyte-mediated cytolysis. Adv Imunol 1992;51:215-42.
15. Henkart P, Henkart M, Millard P et al. The role of cytoplasmatic granules in cytotoxicity by large granular lymphocytes and cytotoxic T lymphocytes. In: Henkart P, Martz E, eds. Mechanisms of Cell-Mediated Cytotoxicity II. New York: Plenum, 1984;184:121-38.
16. Groscurth P, Quiao B-Y, Podack ER, Hengartner H. Cellular localization of perforin 1 in murine cloned cytotoxic T lymphocytes. J Immunol 1987;138:2749-52.
17. Podack ER. Molecular mechanisms of cytolysis by complement and by cytolytic lymphocytes. J Cell Biochem 1986;3:127-36.
18. Carpén O, Säkselä E. Directed exocytosis in the NK cell-mediated cytotoxicity. A review. Nat Immun Cell Growth Regul 1988;7:1-12.
19. Burkhardt JK, Hester S, Lapham CK, Argon Y. The lytic granules of natural killer cells are dual-function organelles combining secretory and pre-lysosomal compartments. J Cell Biol 1990;111:2327-40.
20. Cykes M, Friberg S, Klein G. Progressive loss of H-2 antigen with concomitant increase of cell surface antigen (s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst 1973;50:347-51.
21. 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus. J Natl Cancer Inst 1974;53:1103-11.
22. Glynn JP, McCoy JL, Fefer A. Cross-resistance to the transplantation of syngenic Friend, Moloney and Rouscher virus-induced tumors. Cancer Res 1968;28:434-9.
23. Rosenblum MG, Rios AM, Hersh EM. Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2). Cancer Chemother Pharmacol 1986;18:243-6.
24. Morahan PS, Barnes DW, Munson AE. Relationship of molecular weight to antiviral and antitumor activities and effect of maleic anhydride-divinylether (MVE) polyanions. Cancer Treat Rep 1979;62:1977-83.
25. Cassone A, Marconi P, Bistoni F et al. Immunoadjuvant effects of Candida albicans and its cell wall fractions in a mouse lymphoma model. Cancer Immunol Immunother 1981;10:181-90.
26. Lodder J. The Yeast, a Taxonomic Study, 2nd edn. Amsterdam: North-Holland. 1970.
27. Marconi P, Scaringi L, Tissi L et al. Induction of natural killer cell activity by inactivated Candida albicans in mice. Infect Immun 1985;50:297-303.
28. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 1989;142: 1748-54.
29. Grimm EA, Robb RJ, Roth JA et al. Lymphokine-activated killer cells phenomenon. III. Evidence that IL-2 alone is sufficent for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 1983;158:1356-61.
30. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295-315.
31. Hall TJ, Chen SH, Brostoff J, Lydyard PM. Modulation of human natural killer cell activity by pharmacological mediators. Clin Exp Immunol 1983;54:493-500.
32. Trinchieri G. Biology of natural killer cells. Ad Immunol 1989;47:187-375.
33. Brunda MJ, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980;124:2682-7.
34. Santoni A, Riccardi C, Barlozzari T, Herberman RB. Suppression of activity of mouse natural killer (NK) cells by activated macrophages from mice treated with pyran copolymer. Int J Cancer 1980;26:837-43.
35. 2. J Exp Med 1994;180:2365-70.
36. Lala PK. In: Abraham S. ed. Carcinogenesis and Dietary Fat. Boston: Kluwer Academic Publishers, 1989:219-32.
37. Kay HD, Smith DL. Regulation of human lymphocyte-mediated natural killer (NK) cell activity. I. Inhibition of in vitro by peripheral blood granulocytes. J Immunol 1983;130:475-83.
38. Shau H, Kim A. Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 1988;141:4395-402.
39. Shau H, Golub SH. Inhibition of lymphokine-activated killer-and natural killer-mediated cytotoxicities by neutrophils. J Immunol 1989;143:1066-72.
40. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin 2 augments natural killer cell activity. Nature (London) 1981;291:335-8.
41. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Sheehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin-2. J Exp Med 1984;160:1147-69.
42. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cells phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-41.
43. Specter S, Rivenbark M, Newton C, Kawakami Y, Lancz G. Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin 2. Int J Immunopharmacol 1989;11:63-9.
44. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990;145:244-52.
45. Liu CC, Perussia B, Cohn ZA, Young JD. Identification and characterization of a pore-forming protein of human peripheral blood NK cells. J Exp Med 1986;164:2061-76.
46. Young JD, Cohn ZA. Cellular and humoral mechanisms of cytotoxicity: structural and functional analogies. Adv Immunol 1987;41P:269-332.
47. Takayama H, Trenn G, Humphrey W, Bluestone JA, Henkart PA, Sitkowsky MV. Antigen-receptor triggered secretion of a trypsin-type esterase from cytotoxic T lymphocytes. J Immunol 1987;138:566-72.
48. Zucker-Franklin D, Yang J, Fuks A. Different enzyme classes associated with human natural killer cells may mediate disparate functions. J Immunol 1984;132:1451-5.
49. Hudig D, Greeg NJ, Kam CM, Powers J. Lymphocyte granulemediated cytolysis requires serine protease activity. Biochem Biophys Res Commun 1987;149:882-8.
50. Duke RC, Cohen JJ, Chervenak R. Differences in target cell DNA fragmentation induced by mouse cytotoxic T lymphocytes and natural killer cells. J Immunol 1986;137:1442-7.
51. Nabholz M, Cianfrigliua M, Acuto OA et al. Cytolytically active murine T cell hybrids. Nature 1980;287:437-42.
52. + cytotoxic T lymphocytes and cloned cytotoxic T cell lines. Immunol Rev 1988;103:111-25.
53. Iwata H, Iwata C, Matsudu T. Difference between two isozymes of (Na+/K+)-ATPase in the interaction with omeprazole. Jpn J Pharmacol 1988;46:35-42.
54. Yamamoto O, Tanaka H, Ueda F, Kimura K. Inhibition of H+/ K+ ATPase by methyl (E)-2-(3,4-dimethoxystyryl)-benzimidazole-4-carboxilate (ALE-36). Scand J Gastroenterol Suppl. 1989;162:178-81.
55. Anderson R, Smit MJ. Clofazimine and B669 inhibit the proliferative responses and Na+/K+ adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism. Biochem Pharmacol 1993;46:2029-38.
56. Anderson R, Smit MJ, Van Rensburg CE. Lysophospholipid-mediated inhibition of Na+/K+ adenosine triphosphatase is a possible mechanism of immunosuppressive activity of cyclosporin A. Mol Pharmacol 1993;44:605-14.
57. + T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993;90:10188-92.
58. H1 cells. Immunol Today 1993;14:335-8.
59. Fitch FL, Lancki DW, Gajewski TF. T-cell-mediated immune regulation. Help and suppression. In: Paul W, ed. Fundamental Immunology. New York: Raven Press, 1993: 733-61.